📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. (2019)

First Author: Tweed CD

Attributed to: Tuberculosis Treatment Trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2213-2600(19)30366-2

PubMed Identifier: 31732485

Publication URI: http://europepmc.org/abstract/MED/31732485

Type: Journal Article/Review

Volume: 7

Parent Publication: The Lancet. Respiratory medicine

Issue: 12

ISSN: 2213-2600